Connect with us

Featured

Assange Will See His Day In Court

Daniel Chase

Published

on

stock_price_assange

If we consider, for sake of argument, that declassified data is the most valuable resource a country can possess, then it would make sense that a nation’s government would lose their collective minds if their data was compromised. Over a decade ago, a man by the name of Julian Assange founded WikiLeaks, a website dedicated to releasing declassified government documents to the public in the name of global transparency. Assange’s actions earned him the colloquial label of being a “whistleblower.”

If you’ve yet to study political science or just simply don’t understand several words in the English language, a whistleblower is any person who learns of unethical/illegal activity and reports it to the proper authorities. From a legal standpoint, when someone working at a company does this, it is illegal to share their name with other employees, and one would assume the U.S. government would hold true to the same ideals. 

Regrettably for Mr. Assange, this was not the case. 

In the year after the website went live, WikiLeaks had over 1.2 million declassified documents in its database. Though this was, at the time, a significant amount of information released to the public by the site, it wasn’t until 2010 that WikiLeaks took center stage for the world to see. In April 2010, the whistleblower website posted released secret documents pertaining to American military involvement in Iraq and Afghanistan, including graphic “videos of U.S. bomb strikes on civilians,” according to the site at the time. 

In the video released from WikiLeaks, an airstrike from an Apache helicopter gun-sight shows the unprovoked attack on Iraqi civilians that resulted in the death of twelve people, among them was Reuters photographer, Namir Noor-Eldeen. The released video, albeit graphic and desensitizing, was the first glimpse Americans got into what actually takes place between the U.S. military and the countries they engage in conflict. 

Using the power of modern time-traveling technology, let’s get everyone up to snuff. As of Thursday morning, Assange was arrested inside the Ecuadorian embassy for breaching his previously set bail conditions. According to the most recent statement released by the British Metropolitan Police:

“Julian Assange, 47, (03.07.71) has today, Thursday 11 April, been further arrested on behalf of the United States authorities, at 10:53hrs after his arrival at a central London police station. This is an extradition warrant under Section 73 of the Extradition Act. He will appear in custody at Westminster Magistrates’ Court as soon as possible…”

MET Police Statement 

Per the arrest details released via WikiLeak’s official twitter account, Assange was taken into custody under a U.S. extradition warrant on conspiracy charges for releasing classified information in partnership with former army intelligence analyst, Chelsea Manning. Following his arrest, the United States Justice Department’s prosecutors confirmed that Assange is being accused of trying to hack into a classified U.S. computer. According to TechCrunch, Assange and Manning allegedly worked together to figure out the password to gain entrance onto a U.S. government server, referred to as SIPRNET. 

What’s incredibly interesting and worth paying attention to is the response time from U.S. government officials at the slight chance that Assange was en route to discovering damaging information. In general, the documents and photographs released through WikiLeaks contained information that, for the most part, should’ve been made public quite some time ago. As a whistle blower, Assange was purely trying to let Americans know what the U.S. government has been up to.

Prior to his arrest earlier today, Assange had been living in the Ecuadorian embassy which, as most people know, constitutes living on foreign soil. Because of this fact, the U.S.government had to go through the process of working with U.K officials to extradite Assange so that he could be tried on British soil. 

Continue Reading
Click to comment

Biotechnology

Will Biotech Stocks Soar Into 2020?

Joe Samuel

Published

on

best biotech stocks to trade now

The stock market has been on a wild ride this year and December has shown no difference. When it comes down to it, making money in the stock market is simple. But it isn’t easy; let me explain.

For instance, if a sector is on the upward trajectory then it makes complete sense to have a look at some of the stocks in that arena. But then again, even if the sector is hot, it doesn’t mean every stock within it is.

Regardless, among the sectors that have shown impressive growth over the past few years biotech remains positive. and many investors have managed to make handsome returns. Here is a look at two biotech stocks that are worth considering at this point.

Tonix Pharmaceuticals Holding

The first biotech stock that could be out into the watch list is that of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) after the company made an important announcement. Tonix announced that it has been granted a patent by the European Patent Office for “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Mannitol”.

The patent gives Tonix access to as many as 14 claims and also gives the company exclusive rights up until 2034. The development is a significant one and could have far-reaching implications for Tonix’s business in the years to come.The news was well-received by the markets as well and the stock rallied by as much as 23% on Thursday.

VBI Vaccines

The other stock that could be taken under consideration is the VBI Vaccines Inc (NASDAQ:VBIV). The company made a major announcement with regards to the Phase 1/2A study of its cancer vaccine immunotherapeutic In recurrent glioblastoma (GBM) patients medicine VB1-1901.

The company announced that it presented the data regarding the medicine at the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology. The event in question is an influential one and is a substantial achievement for VBI. The stock rallied by as much as 50%.

Continue Reading

Featured

Stock Price Newsletter – December 13, 2019

Joe Samuel

Published

on

stock market news

StockPrice Special Report: The $40 Billion Dollar Content Gold Rush

Click For Full Report


2 Biotech Stocks To Watch Before Next Week

See For Yourself


Streaming Wars and the Future of Companies Involved

Has The Time Come?

Continue Reading

Biotechnology

2 Biotech Stocks To Watch Before Next Week

A. Lawrence

Published

on

stock_price_medicine

Biotech has been one of the hottest sectors to invest in for quite a few years. Nowadays, investors are almost always on the lookout for the next big thing from among those stocks. However, when it comes to identifying stocks, an investor needs to do his fair share of research and then decide on his next course of action.

Additionally, one could also watch the market closely and keep track of the latest movements in penny stocks in order to identify potential winners. Here is a look at two biotech stocks which could be of interest to investors.

Biotech Stocks To Watch: Marinus Pharmaceuticals

The first biotech stock to bring under consideration is Marinus Pharmaceuticals Inc (NASDAQ:MRNS)  which has made significant gains on Wednesday on the back of an important announcement.

top biotech stocks to buy

On Wednesday, the company announced that it is going to make a simultaneous public offering of its common stock and private placement. The total value of these two offerings is going to be $65 million. The news resulted in a 38% bump in the stock price in yesterday’s trading session.

Earlier this week, the company announced that it has started its Phase 2 trial for its product ganaxolone as well. The medicine in question is supposed to treat tuberous sclerosis complex and it goes without saying that it is a significant milestone for Marinus.

Biotech Stocks To Watch: Diffusion Pharmaceuticals

top biotech stocks to buy now

The other biotech stock that could be worth tracking is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN). The company announced positive data with regards to the Phase 3 study its product Trans Sodium Crocetinate (TSC) plus standard of care (SOC). The data showed that there was an improvement in the condition of patients suffering from inoperable glioblastoma multiforme.

It proved to be a major trigger for the Diffusion stock and after the announcement was made on Tuesday, the stock has rallied by as much as 31.40%. It is a stock that could be worth watching over the coming days.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com